{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T07:45:35Z","timestamp":1784447135845,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Pfizer LATAM","award":["88792339"],"award-info":[{"award-number":["88792339"]}]},{"name":"Pfizer LATAM","award":["88792339"],"award-info":[{"award-number":["88792339"]}]},{"name":"Pfizer LATAM","award":["88792339"],"award-info":[{"award-number":["88792339"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14526-7","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:25:39Z","timestamp":1755613539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Days alive and out of hospital in patients with wild type transthyretin amyloidosis: cohort study"],"prefix":"10.1038","volume":"15","author":[{"given":"Mariana","family":"Vaena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Adela","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teo","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Schalum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facundo Ezequiel","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Lourdes","family":"Posadas-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2259-5626","authenticated-orcid":false,"given":"Marcelina","family":"Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"14526_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nrneph.2013.171","volume":"9","author":"JD Gillmore","year":"2013","unstructured":"Gillmore, J. D. & Hawkins, P. N. Pathophysiology and treatment of systemic amyloidosis. Nat. Rev. Nephrol. 9, 574\u2013586 (2013).","journal-title":"Nat. Rev. Nephrol."},{"key":"14526_CR2","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","volume":"382","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran, S., Lachmann, H. J. & Wechalekar, A. D. Epidemiologic and survival trends in amyloidosis, 1987\u20132019. N. Engl. J. Med. 382, 1567\u20131568 (2020).","journal-title":"N. Engl. J. Med."},{"key":"14526_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","volume":"12","author":"LG Gilstrap","year":"2019","unstructured":"Gilstrap, L. G. et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ. Heart Fail. 12, e005407 (2019).","journal-title":"Circ. Heart Fail."},{"key":"14526_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.recesp.2011.05.003","volume":"64","author":"P Garc\u00eda-Pav\u00eda","year":"2011","unstructured":"Garc\u00eda-Pav\u00eda, P., Tom\u00e9-Esteban, M. T. & Rapezzi, C. Amyloidosis. Also a heart disease. Rev. Esp. Cardiol. 64, 797\u2013808 (2011).","journal-title":"Rev. Esp. Cardiol."},{"key":"14526_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","volume":"12","author":"MS Maurer","year":"2019","unstructured":"Maurer, M. S. et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ. Heart Fail. 12, e006075 (2019).","journal-title":"Circ. Heart Fail."},{"key":"14526_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum, M. H. et al. Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): A targeted literature review. Cardiol. Ther. 10, 141\u2013159 (2021).","journal-title":"Cardiol. Ther."},{"key":"14526_CR7","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore, J. D. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133, 2404\u20132412 (2016).","journal-title":"Circulation"},{"key":"14526_CR8","first-page":"102","volume":"12","author":"M Magdi","year":"2022","unstructured":"Magdi, M. et al. A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction. Am. J. Cardiovasc. Dis. 12, 102\u2013111 (2022).","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"14526_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","volume":"6","author":"OF AbouEzzeddine","year":"2021","unstructured":"AbouEzzeddine, O. F. et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 6, 1267\u20131274 (2021).","journal-title":"JAMA Cardiol."},{"key":"14526_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.recesp.2024.07.008","volume":"78","author":"P Garc\u00eda-Pav\u00eda","year":"2025","unstructured":"Garc\u00eda-Pav\u00eda, P. et al. Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: The PRACTICA study. Rev. Esp. Cardiol. (Engl. Ed). 78, 301\u2013310 (2025).","journal-title":"Rev. Esp. Cardiol. (Engl. Ed)."},{"key":"14526_CR11","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","volume":"41","author":"L Chacko","year":"2020","unstructured":"Chacko, L. et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur. Heart J. 41, 1439\u20131447 (2020).","journal-title":"Eur. Heart J."},{"key":"14526_CR12","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore, J. D. et al. A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39, 2799\u20132806 (2018).","journal-title":"Eur. Heart J."},{"issue":"8","key":"14526_CR13","first-page":"1275","volume":"37","author":"T Re Kawada","year":"2022","unstructured":"Re Kawada, T. et al. Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databases. Curr. Med. Res. Opin. 37(8), 1275\u20131281 (2022).","journal-title":"Curr. Med. Res. Opin."},{"key":"14526_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.004755","volume":"11","author":"AC Fanaroff","year":"2018","unstructured":"Fanaroff, A. C. et al. Days alive and out of hospital: Exploring a patient-centered, pragmatic outcome in a clinical trial of patients with acute coronary syndromes. Circ Cardiovasc. Qual. Outcome. 11, e004755 (2018).","journal-title":"Circ Cardiovasc. Qual. Outcome."},{"key":"14526_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.ahj.2011.08.003","volume":"162","author":"CA Ariti","year":"2011","unstructured":"Ariti, C. A. et al. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am. Heart J. 162, 900\u2013906 (2011).","journal-title":"Am. Heart J."},{"key":"14526_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/13506129.2019.1582017","volume":"26","author":"J Rubin","year":"2019","unstructured":"Rubin, J., Teruya, S., Helmke, S., De Los Santos, J. & Alvarez MS Maurer, J. Days alive and outside of hospital from diagnosis of transthyretin vs light chain cardiac amyloidosis. Amyloid 26, 4\u20135 (2019).","journal-title":"Amyloid"},{"key":"14526_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.bja.2019.07.020","volume":"123","author":"SR Moonesinghe","year":"2019","unstructured":"Moonesinghe, S. R. et al. Systematic review and consensus definitions for the standardised endpoints in perioperative medicine initiative: Patient-centred outcomes. Br. J. Anaesth. 123, 664\u2013670 (2019).","journal-title":"Br. J. Anaesth."},{"key":"14526_CR18","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia, P. et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 42, 1554\u20131568 (2021).","journal-title":"Eur. Heart J."},{"key":"14526_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1161\/CIRCHEARTFAILURE.111.962688","volume":"4","author":"AM Chamberlain","year":"2011","unstructured":"Chamberlain, A. M., Redfield, M. M., Alonso, A., Weston, S. A. & Roger, V. L. Atrial fibrillation and mortality in heart failure: a community study. Circ. Heart Fail. 4, 740\u2013746 (2011).","journal-title":"Circ. Heart Fail."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14526-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:09:48Z","timestamp":1757477388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14526-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14526"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14526-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study protocol relied on a limited, secondary data set and was approved by the Comit\u00e9 de \u00c9tica de Protocolos de Investigaci\u00f3n of the Hospital Italiano de Buenos Aires (IRB) under number 7980, which waived the requirement for informed consent. This research was conducted in compliance with ethical principles consistent with national and international regulatory standards for human health research, in accordance with National Ministerial Resolution No. 1480\/2011, Law 3301\/09 of the Ciudad Aut\u00f3noma de Buenos Aires, the Declaration of Helsinki, and in compliance with ICH E6 Good Clinical Practice Standards. This study is retrospective in nature, and the requirement for informed consent was waived by the Comit\u00e9 de \u00c9tica de Protocolos de Investigaci\u00f3n of the Hospital Italiano de Buenos Aires in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"30396"}}